Amiocordin - Instructions For Use, Indications, Doses, Analogues

Table of contents:

Amiocordin - Instructions For Use, Indications, Doses, Analogues
Amiocordin - Instructions For Use, Indications, Doses, Analogues

Video: Amiocordin - Instructions For Use, Indications, Doses, Analogues

Video: Amiocordin - Instructions For Use, Indications, Doses, Analogues
Video: How Should Amiodarone Be Started and Managed? 2024, May
Anonim

Amiocordin

Instructions for use:

  1. 1. Release form and composition
  2. 2. Indications for use
  3. 3. Contraindications
  4. 4. Method of application and dosage
  5. 5. Side effects
  6. 6. Special instructions
  7. 7. Drug interactions
  8. 8. Analogs
  9. 9. Terms and conditions of storage
  10. 10. Terms of dispensing from pharmacies
Amiocordin tablets
Amiocordin tablets

Amiocordin is a class III antiarrhythmic drug with an antianginal effect.

Release form and composition

Amiocordin is available in the following forms:

  • Tablets: biconvex, round, white or white with a cream shade, there is a risk on one side (10 pieces in blisters, in a cardboard box of 3, 6 or 50 packages; for hospitals - 100 packages in a cardboard box);
  • Solution for intravenous administration: transparent, slightly yellowish, no visible mechanical inclusions (3 ml in ampoules, 5 ampoules in blisters, 1 blister in a cardboard box; for hospitals - 20 blisters in a cardboard box).

Composition of 1 tablet:

  • Active ingredient: amiodarone hydrochloride - 200 mg;
  • Auxiliary components: povidone, magnesium stearate, lactose monohydrate, anhydrous colloidal silicon dioxide, corn starch.

Composition of 1 ml solution:

  • Active ingredient: amiodarone hydrochloride - 50 mg;
  • Auxiliary components: polysorbate 80, benzyl alcohol, water for injection.

Indications for use

  • Life-threatening ventricular arrhythmias (including ventricular tachycardia);
  • Supraventricular arrhythmias (more often when other treatment is impossible or ineffective), including paroxysm of atrial flutter and atrial fibrillation;
  • Arrhythmias associated with chronic heart failure or coronary insufficiency;
  • Ventricular arrhythmias in patients with Chagas myocarditis;
  • Ventricular and atrial premature beats;
  • Prevention of angina attacks;
  • Relief of parasystole;
  • Prevention of ventricular fibrillation.

Contraindications

Absolute:

  • Sinoatrial blockade;
  • Cardiogenic shock;
  • Collapse;
  • Sinus bradycardia;
  • Arterial hypotension;
  • Sick sinus syndrome;
  • Interstitial lung disease;
  • Severe respiratory distress;
  • AV block II-III degree (provided that the pacemaker is not used);
  • Thyrotoxicosis;
  • Hypokalemia;
  • Hypothyroidism;
  • The period of pregnancy and breastfeeding;
  • Concomitant use of monoamine oxidase inhibitors;
  • Hypersensitivity to iodine and / or any component of the drug.

Relative (Amiocordin is used with caution):

  • Liver failure;
  • Chronic heart failure;
  • Elderly age;
  • Bronchial asthma;
  • Children and adolescents up to 18 years old (there is no data on the effectiveness of the drug and its safety during use in children).

Method of administration and dosage

Tablets

Amiocordin tablets are taken orally, during or after meals. They should be swallowed whole with water. For adult patients, the drug is prescribed in an initial single dose of 200 mg. The initial daily dose is 600-800 mg, the maximum daily dose is 1200 mg. Frequency rate of application - 2-3 times a day. The duration of therapy is 8-15 days.

The maintenance dose of Amiocordin is 100-400 mg per day in 1-2 doses. The minimum effective dose of the drug is recommended. It can be taken every other day in a double dose.

For patients over 75 years old, the drug is prescribed in the minimum effective doses (both initial and maintenance).

Solution for intravenous administration

Solution for injection Amiocordin is intended exclusively for use in a hospital setting, when oral administration of the drug is impossible or the achievement of an antiarrhythmic effect is required urgently. For intravenous jet or drip administration, a single dose is 5 mg per kg of body weight, the daily dose is up to 15 mg per kg of body weight (but not more than 1200 mg).

For patients over 75 years old, the drug is prescribed in the minimum effective doses (both initial and maintenance).

Side effects

  • Digestive system: decreased appetite, abdominal pain, vomiting and nausea, feeling of heaviness in the epigastric region, loss or dullness of taste, diarrhea or constipation, flatulence; rarely - increased activity of liver transaminases; with long-term treatment - cholestasis, liver cirrhosis, toxic hepatitis, jaundice;
  • Respiratory system: with long-term treatment - shortness of breath, pleurisy, cough, pulmonary fibrosis, alveolitis or interstitial pneumonia; with intravenous administration - apnea, bronchospasm (in patients with severe respiratory failure);
  • Cardiovascular system: AV block, bradycardia; with long-term treatment - the occurrence or intensification of the existing arrhythmia, ventricular arrhythmia of the "pirouette" type, progression of chronic heart failure; with intravenous administration - lowering blood pressure;
  • Hematopoietic system: aplastic and hemolytic anemia, thrombocytopenia;
  • Central and peripheral nervous system: depression, paresthesia, weakness, auditory hallucinations, dizziness and headache, fatigue; with long-term treatment - ataxia, impaired memory and sleep, tremor, optic neuritis, peripheral neuropathy, extrapyramidal disorders; with intravenous administration - increased intracranial pressure;
  • Sensory organs: retinal microdetachment, lipofuscin pigment deposition in the epithelium of the cornea of the eye, uveitis;
  • Endocrine system: hyper- or hypothyroidism;
  • Dermatological reactions: exfoliative dermatitis, alopecia, photosensitivity, skin rash; rarely - staining of the skin in a gray-blue color;
  • Local reactions (with intravenous administration): thrombophlebitis;
  • Other reactions: vasculitis, myopathy, inflammation of the epididymis, decreased potency; with intravenous administration - increased sweating, fever.

special instructions

Before starting therapy with Amiocordin, as well as with prolonged therapy, the function of the thyroid gland should be monitored and an x-ray of the lungs should be performed, if necessary, electrolyte disturbances should be corrected. During treatment, you should regularly visit an ophthalmologist.

Intravenous administration is carried out under constant monitoring of heart rate, blood pressure and ECG.

During treatment, patients should avoid direct exposure to sunlight.

When the drug is discontinued, recurrence of cardiac arrhythmias may occur.

Amiocordin may interfere with the results of the iodine-concentrating thyroid test.

Drug interactions

Amiocordin should not be used concomitantly with the following drugs: other antiarrhythmics, vincamine, calcium channel blockers, corticosteroids, sultopride, beta-blockers, laxatives, intravenous amphotericin B, intravenous erythromycin, intravenous pentamidine, and diuretics.

Astemizole, tricyclic antidepressants, terfenadine and phenothiazines potentiate the prolongation of the QT interval and the likelihood of ventricular arrhythmia.

Cimetidine slows down the metabolism of amiodarone.

The drug enhances the effects of digoxin, cyclosporin, warfarin and phenytoin.

Analogs

Amiodarone analogs are: Amiodarone, Amiodarone-SZ, Amiodarone Sandoz, Amiodarone-OBL, Amiodarone Belupo, Amiodarone-Acri, Vero-Amiodarone, Cordarone, Cardiodarone.

Terms and conditions of storage

Store in a dark place at a temperature not exceeding 25 ° C. Keep out of the reach of children.

Shelf life: tablets - 5 years, injection solution - 2 years.

Terms of dispensing from pharmacies

Dispensed by prescription.

Information about the drug is generalized, provided for informational purposes only and does not replace the official instructions. Self-medication is hazardous to health!

Recommended: